FDA Says Novo's Wegovy, Injection, .25 mg/.5 ml (NDC 0169-4525-14) Under Limited Availability With Estimated Shortage Duration TBD; Wegovy, Injection, .5 mg/.5 ml (NDC 0169-4505-14) Under Limited Availability With Estimated Shortage Duration TBD; Wegovy, Injection, 1 mg/.5 ml (NDC 0169-4501-14) Limited Availability With Estimated Shortage Duration TBD
Portfolio Pulse from Benzinga Newsdesk
The FDA has announced that Novo Nordisk's Wegovy, an injection with a dosage of .25 mg/.5 ml (NDC 0169-4525-14), is currently under limited availability. The estimated duration of the shortage is yet to be determined.
April 29, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novo Nordisk's Wegovy injection is under limited availability, with an uncertain duration for the shortage as announced by the FDA.
The announcement of a shortage and limited availability of a key product like Wegovy can lead to negative investor sentiment towards Novo Nordisk in the short term. This is due to potential impacts on sales and revenue, especially if the shortage lasts for an extended period. The uncertainty around the duration of the shortage adds to the negative outlook, as it makes it difficult for investors to gauge the potential financial impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100